These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6427477)

  • 1. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
    Winfield H; Trachtenberg J
    J Urol; 1984 Jun; 131(6):1107-9. PubMed ID: 6427477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
    Trachtenberg J
    J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
    Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
    Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
    Smith JA
    Urology; 1986 Jan; 27(1 Suppl):9-15. PubMed ID: 3079936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.
    Thompson IM; Zeidman EJ; Rodriguez FR
    J Urol; 1990 Dec; 144(6):1479-80. PubMed ID: 2122011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
    Chodak GW
    Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
    Garnick MB
    Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.
    Sharifi R; Lee M; Ojeda L; Ray P; Stobnicki M; Guinan P
    Urology; 1985 Aug; 26(2):117-24. PubMed ID: 3927551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
    Leuprolide Study Group
    N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
    Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
    Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.
    Stein BS; Smith JA
    Urology; 1985 Apr; 25(4):350-3. PubMed ID: 3920802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients].
    Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K
    Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
    Rajfer J; Swerdloff RS; Heber DM
    Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.